Build A Bear Workshop Inc vs Inovio Pharmaceuticals Inc — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $461.88M), while Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M). The key difference: Build A Bear Workshop Inc is far larger — about 5.9× Inovio Pharmaceuticals Inc's market cap, and Build A Bear Workshop Inc pays a 2.5% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BBW | INO | |
|---|---|---|
Market Cap | $461.88M | $78.55M |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $2.87 |
52-Week Low | $29.84 | $0.66 |
Enterprise Value | $561.32M | $49.56M |
Dividend Yield | 2.5% | — |
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.
The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →